Polyrizon Completes Participant Enrollment In Its Trial Of NASARIX To Treat Airborne Allergens

Benzinga · 2d ago

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful completion of patient enrollment and randomization in its U.S. multicenter clinical study evaluating NASARIX, the Company's proprietary investigational nasal hydrogel product candidate designed to provide protection against airborne allergens.

The study has reached its planned enrollment target, with 120 participants randomized across five clinical research sites in the United States. A total of 144 individuals were screened to achieve the enrollment target.